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Abstract Focal lesions and brain atrophy are the most
extensively studied aspects of multiple sclerosis (MS), but
the image acquisition and analysis techniques used can be
further improved, especially those for studying within-
patient changes of lesion load and atrophy longitudinally.
Improved accuracy and sensitivity will reduce the numbers
of patients required to detect a given treatment effect in a
trial, and ultimately, will allow reliable characterization of
individual patients for personalized treatment. Based on
open issues in the field of MS research, and the current
state of the art in magnetic resonance image analysis
methods for assessing brain lesion load and atrophy, this
paper makes recommendations to improve these measures
for longitudinal studies of MS. Briefly, they are (1) images
should be acquired using 3D pulse sequences, with near-
isotropic spatial resolution and multiple image contrasts to
allow more comprehensive analyses of lesion load and
atrophy, across timepoints. Image artifacts need special
attention given their effects on image analysis results. (2)
Automated image segmentation methods integrating the
assessment of lesion load and atrophy are desirable. (3) A
standard dataset with benchmark results should be set up to
facilitate development, calibration, and objective evalua-
tion of image analysis methods for MS.
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Introduction
Longitudinal magnetic resonance imaging (MRI) studies of
focal brain lesions and brain atrophy play an important role
in the study of multiple sclerosis (MS) in that they help to
improve understanding of disease pathobiology [1] and its
clinical and cognitive effects [2], and to investigate the
effect of therapeutic strategies [3, 4]. MRI assessment of
lesion burden and of volumetric changes in the brain cover
both the focal and diffuse aspects of the underlying path-
ological processes and can be achieved using standard
structural imaging pulse sequences. There are, however,
several limitations in their application to the study of MS.
In the brain, while white matter (WM) lesions can easily be
detected using standard proton density (PD)/T2-weighted
or FLAIR imaging, the detection of focal gray matter (GM)
lesions by standard sequences is much less reliable [5], due
to the different tissue composition and pathological sub-
strates [1]. Regarding brain atrophy, volumetric measures
are sensitive to MS-related changes due to neuroaxonal
loss, gliosis, demyelination, and possibly remyelination,
but are also influenced by many other biological factors
such as the degree of edema and hydration status of the
tissues (e.g., [6–8]). In addition, while image acquisition
techniques have already been standardized to a large
degree, the image analysis methods needed to obtain reli-
able measures are not yet standardized and yield variable
results [6, 9]. A recent review of the literature on correla-
tive studies between MRI and histopathology in MS [10]
recommended improvement of imaging specificity, high-
resolution image acquisition, and use of combination of
imaging methods in longitudinal studies to gain a deeper
understanding of the disease processes in MS.
Against this background, this paper focuses on what we
consider desirable future developments in image acquisi-
tion and analysis for the longitudinal assessment of brain
lesions and brain atrophy in MS. Previous guidelines for-
mulated in 1998 [11] regarding quantitative MR image
analysis in MS served as the background against which we
examined the current state of the art to derive recommen-
dations on the development and application of image
analysis methods for optimal assessment of brain lesions
and atrophy in MS. Other important issues, such as the
assessment of lesions and atrophy in the spinal cord and
optic nerve, as well as the heterogeneity of focal lesions
and the patterns of tissue changes in the normal-appearing
brain, were excluded from this paper since, with the pos-
sible exception of spinal cord abnormalities, all these
investigations require more advanced imaging techniques,
hampering large-scale implementation. In the following
sections, for each topic we will first present a brief position
statement followed by the reasoning behind it.
Image acquisition
Position statement
Image acquisition should use isotropic 3D pulse sequences
with multiple image contrasts to improve and extend
analyses of lesions and atrophy, across timepoints. Image
artifacts need special attention since they have significant
effects on image analysis results.
Reasoning
Increasing sensitivity for detecting and quantifying lesion
and atrophy changes
While 2D (i.e., multislice) imaging has certainly proven its
value in diagnosis and research, it is equally clear that with
through-plane spatial resolutions on the order of 3 mm, the
sensitivity for detecting localized subtle tissue changes
over time is limited. One problem that may occur is subject
motion between the acquisition of two interleaved sets of
slices, which can introduce substantial errors in lesion load
measurement as recently described [12]. However, even
when interleaved scanning-related problems are absent or
can be resolved, 2D imaging introduces severe limitations.
Not only do images with anisotropic spatial resolution
contain no information about the spatial distribution of
signal through the slice, but any co-registration between
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images from different timepoints will inevitably introduce
interpolation artifacts. This is not only the case if reposi-
tioning is poor, but even when previously published repo-
sitioning guidelines [11] are followed. For example, in
cases where there is substantial atrophy between scans,
good repositioning of the MR slices cannot circumvent the
need to deform the image in the through-plane direction to
match the brain, which introduces interpolation errors.
Conversely, 3D acquisition schemes offer the advantage of
allowing improved through-plane spatial resolution. This
leads to improved image registration, and also to smaller
interpolation-induced resampling errors, compared to 2D
images with thick slices. It is now feasible on most scan-
ners to acquire 3D image datasets with (near) isotropic
resolution in clinically acceptable scan times [13].
It is more practical to acquire images using 3D pulse
sequences with T1 weighting than with T2 weighting, and
T1-weighted 3D images have become the standard imaging
method for the study of brain atrophy. The application of
other contrasts with 3D imaging in practical scan times is
being made possible through recent efforts combining 3
Tesla scanners, with phased-array receiver coils, parallel
acquisition, and a variable flip angle scheme [14]. Such
developments are crucial to the study of focal WM and GM
lesions with resolution comparable to that achievable in T1-
weighted imaging. It is likely that the assessment of T2
lesion volume change, which is now an outcome measure in
many clinical trials of new putative treatments for MS (e.g.,
[15, 16]), will be more accurate when this improved spatial
resolution is employed. In addition, several techniques can
be tailored to the imaging of GM lesions (DIR, MP-RAGE,
SPGR, PSIR) and can be implemented with 3D acquisition;
these are being systematically evaluated [5, 13, 17–23].
Longitudinal group studies looking for subtle, localized
changes in lesions would also benefit from high-resolution
3D acquisition. One example application is the group-level
lesion probability mapping (LPM) approach, which several
studies have used cross-sectionally [24–29], but few so far
have used to investigate longitudinal changes [30, 31].
Another example is the assessment of localized lesional
change in individual patients through subtraction imaging,
which has been shown to be improved when using near-
isotropic spatial-resolution 3D imaging compared to 2D
imaging. Using 3D images, more active lesions were
detected, and inter-rater reliability was greater than for 2D
images [32]. It should be expected that detecting within-
patient changes and establishing relations at a group level
would be more sensitive to minor differences if better
spatial resolution is employed. Finally, the spatial, tem-
poral, and possibly causal relations between brain lesions
and brain atrophy [30, 33, 34], could be studied better if
both the atrophy and the lesions were imaged with (near)
isotropic spatial resolution of the order of 1 mm.
It would clearly be advantageous to define a set of 3D
imaging techniques with multiple contrasts that capture as
many of the known aspects of brain changes in MS as
possible in both the GM and WM, with optimized image
contrast and good spatial resolution.
Image artifacts
Care must be taken to minimize image artifacts, which can
have a large influence on the results from image analysis.
Common artifacts include radiofrequency (RF) intensity
non-uniformity, phase-encode ghosting, signal wrap, and
geometric distortion due to gradient non-uniformity, and
B0 inhomogeneity. A relevant review can be found here
[35].
Radiofrequency non-uniformity, which results in slow
spatial variations of signal intensity known as the bias field,
is usually partially corrected during image acquisition,
although the increasingly common use of coil arrays and
very high field scanners has led to an increase in the
prevalence, severity, and variability of bias field in most
images. Image analysis methods should include a bias field
correction if necessary, as is commonly done in tissue-type
segmentation methods [36, 37] or using stand-alone cor-
rection methods such as N3 [38].
Phase-encode ghosting artifacts are due to a mismatch
between the true phase of spins and the phase corre-
sponding to their spatial position; the signal from these
spins can then erroneously appear elsewhere in the image.
They arise when a collection of spins moves between phase
encoding and read-out, either through motion of the entire
head (motion artifacts) or flow of blood or CSF (flow
artifacts). Motion of the head should obviously be restric-
ted as much as possible. Blood flow artifacts may yield
substantial distortions of the signal along the phase-encode
direction(s), hampering analysis of those regions. Flow
artifacts due to blood may be diminished by using a pre-
saturation slab on the neck to minimize signal emanating
from the blood entering the head. Flow artifacts, which
increase with gadolinium injection particularly at the pos-
terior fossa, can also be minimized by reduction of phase
shifts with flow compensation or gradient moment nulling,
but with the penalty of increasing the echo time.
The wrap-around artifact is most frequently observed in
a sagittally or coronally oriented 3D acquisition with tight
planning of the volume in the anterior–posterior direction,
where the nose wraps into the occipital lobe or cerebellum.
However, for multiarray coils with parallel imaging, such
artifacts can also occur within the brain. To allow whole-
brain analyses, wrap-around artifacts, if unavoidable,
should be kept outside brain voxels. For methods requiring
information outside the brain, such as SPM-VBM, it may
also be necessary for the subcutaneous fat and skin to be
2460 J Neurol (2013) 260:2458–2471
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kept clear of such artifacts. This can be achieved by proper
choice of the read-out direction and field-of-view, albeit
probably sometimes at the cost of increased scan time.
Non-uniformity of imaging gradients gives rise to geo-
metric distortion, due to a violation of the assumption of a
linear relation between field strength and true spatial
position. When uncorrected, this has been shown to sub-
stantially affect whole-brain and local atrophy rate mea-
surement [39, 40]. The correction to remove the geometric
distortion [41] does come at the cost of an additional image
interpolation step which affects all subsequent analyses
(although some recent, so far unpublished work has been
done to combine this with other interpolations into a single
step), but even so, for some analysis software (e.g., SIENA
[42]) the beneficial effects of removing the distortion are
greater than the potential loss of accuracy due to this
additional interpolation [40].
B0 inhomogeneities also give rise to geometric distor-
tion, but additionally cause signal intensity loss due to
more rapid dephasing. Signal loss can be minimized by
using spin–echo pulse sequences with high receiver band-
widths (high gradient strength); by acquiring for each slice
a pair of images with opposite polarity gradients; or by
applying a post hoc correction based on direct measure-
ment of a B0 map. However, it is worth noting that B0
inhomogeneities are not normally significant for the type of
images under consideration here, except in very high field
strength scanners or with pulse sequences with long gra-
dient echo train lengths.
For completeness, we should also consider poor SNR
and tissue contrast as obvious factors influencing poor
image analysis outcomes. Optimizing SNR and tissue
contrast through choice of field strength, pulse sequence
design, and optimization of sequence parameters prior to
initiation of a study is imperative. Table 1 lists these arti-
facts and possible solutions.
Image analysis
Position statement
Improved automated image segmentation is needed to
overcome the limitations of existing methods. They should
be directed toward providing an integrated assessment of
lesions and atrophy.
Reasoning
Standardizing lesions and atrophy measurement
Volumetric quantification of the changes in lesion load and
cerebral atrophy depends crucially on tissue-type segmen-
tation, which is influenced by both acquisition- and dis-
ease-related factors. Focusing on the disease-related
factors, several recent studies have shown that the extent of
WM lesions can influence GM atrophy measurements
because WM lesions have MR properties similar to those
of GM [43–48]. An interesting approach that has been
proposed to counter this problem is lesion inpainting,
whereby signal intensities of lesion voxels are substituted
with those observed in normal-appearing WM, prior to
further analysis [43, 45, 48]. Although this appears to be a
Table 1 Image artifacts and possible solutions
Image artifact Possible solution Limitation or
negative effect of
proposed solution
Spatial signal
intensity variation
due to RF field
inhomogeneity
(bias field)
Measure RF bias
field at acquisition
Parallel transmission
becoming
available on latest
generation of
scanners
Correct using bias
field correction
algorithm
–
Wrap-around artifacts Change read-out
direction and field-
of-view
Probable increase in
acquisition duration
Ghosting artifacts
(motion)
Make patient as
comfortable as
possible
Limit duration of
acquisition
Too short an
acquisition will lead
to unacceptably low
signal-to-noise ratio
Ghosting artifacts
(blood and CSF
flow)
Apply pre-saturation
slab on neck, or
perform flow-
compensated
acquisition
Effects on acquisition
duration and
outcome measures
to be evaluated
Geometric distortion
due to gradient non-
uniformity
Correct using
existing algorithms
Additional
interpolation; for
SIENA analysis,
any negative effects
seem to be
outweighed by
benefits
B0 inhomogeneity
(usually limited)
Shorten TE and use
higher strength
imaging gradients
Apply post hoc
correction
Not always possible;
can compromise
signal-to-noise ratio
Additional
measurement of B0
required
Poor SNR and/or
tissue contrast
Optimize pulse
sequence design
and parameter
values
SNR increase at
unchanged
resolution may lead
to increased
acquisition
duration; trade-off
to be made
J Neurol (2013) 260:2458–2471 2461
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promising approach yielding seemingly improved atrophy
measurements [44, 46], the effect of the correction may
change with the lesion load and the specific algorithms
used for correction and segmentation. For the FAST seg-
mentation software from FSL [37], the choice of partial
volume modeling algorithm utilized by the segmentation
method was shown to exert a clear influence [43]. An
obvious limitation of the lesion inpainting approach is that
the lesion voxels still have to be identified and correctly
segmented before new intensities can be assigned to them
prior to GM segmentation.
Ideally, however, tissue segmentation methods for lon-
gitudinal studies of MS should tackle these issues auto-
matically, and we recommend that this should be done by
concurrently analyzing all tissue classes. Indeed, an
attempt at integrated segmentation including both lesion
and atrophy assessments for a single timepoint has already
been reported [47, 49]. The inclusion of all timepoints
available for a patient in a single segmentation process is
another step that might improve quantification. Such con-
current analysis of multiple timepoints for one patient has
been implemented in the CLADA software for longitudinal
cortical atrophy measurement [50] and in the FreeSurfer
software package for cortical thickness measurement and
deep GM volumetry [51], while another paper demon-
strated how difference images, obtained by subtracting co-
registered images from two timepoints, may be used in the
automated quantification of lesion volume change [52].
Development of this type of integrated analysis may
take substantial amounts of time, and not all issues may be
solvable. It would therefore be prudent to investigate
alternative approaches; such approaches could be informed
by a detailed analysis of the errors that occur when
applying current methods to data already collected in
longitudinal studies of MS. While the ‘‘holy grail’’ of a
comprehensive segmentation method accessible by all
researchers in the field should still be pursued, improve-
ment of existing techniques may be a useful alternative
approach.
Most frequent sources of errors
Errors in image analysis in MS studies can be grouped into
two main categories: poor registration quality, and poor
tissue segmentation. In many analyses, the final tissue
segmentation is preceded by an algorithm to (approxi-
mately) find the intracranial cavity [53, 54]; in that case, a
third category is the incorrect inclusion of extracranial
tissue in the final segmentation. Errors in each of these
categories are often the result of one of a few main causes:
• pathological changes, such as severe atrophy or large
WM lesion load;
• image acquisition-related factors, such as incomplete
head coverage, inadequate spatial resolution (leading to
substantial partial volume effects), poor tissue contrast,
limited SNR, and artifacts;
• inherent limitations of the algorithm, possibly aggra-
vated by image acquisition-related factors.
Beyond the obvious (partial) solutions of both optimiz-
ing the image acquisition for the desired analysis (e.g.,
using full-head coverage whenever possible), and opti-
mizing the analysis algorithms, there are several additional
steps that allow relatively easy correction or prevention of
such errors, which give substantial improvements to the
quality of the analyses. For group studies, registration
errors due to the presence of severe pathology may be
limited by using disease group-specific templates rather
than standard healthy control templates, together with
appropriate regularization of the registration [55]. How-
ever, when there are large pathological changes within a
single patient, adequate non-linear matching between
timepoints remains challenging. Errors in segmentation
may be limited by using information from more than one
image type, ideally in an integrated segmentation approach
as recommended above. For both these issues, challenges
remain, and solving both might be facilitated by the stan-
dardized test dataset discussed under recommendation (3).
Progress has recently been made in the initial segmen-
tation of the intracranial cavity, often referred to as ‘‘brain
extraction’’. Brain extraction is often imperfect, leaving
tissue around the eyes and optic nerves, or removing part of
the brain tissue, thus potentially introducing large errors in
atrophy measurements by tools that rely on the brain
extraction accuracy. A previous study showed that for 2D
images, manual correction of the brain extraction used by
SIENA (BET) increases sensitivity to disease effects in MS
[56], but this solution is not feasible for high-resolution 3D
images due to the high workload that would be generated.
In this case, the brain extraction option settings should be
optimized until the best compromise in brain extraction is
obtained across all the images to be analyzed. However, a
recent paper showed that a single combination of option
settings yielded quantitatively very good results across a
range of 3D T1-weighted image types in MS patients [57],
obviating the need for further adjustment.
Lesions
Many lesion segmentation algorithms have been proposed,
and a useful recent review is given in [58]. We restrict the
scope here to fully automated methods and those that
require minimal user intervention. The methods are based
on several different principles such as intensity threshold-
ing (e.g., [59, 60]), intensity gradient features (e.g., [61]),
2462 J Neurol (2013) 260:2458–2471
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intensity histogram modeling of the expected tissue classes
(e.g., [49, 62, 63]), identification of nearest neighbors (from
a training data set) in a feature space (e.g., [64–66]), or
fuzzy connectedness (e.g., [67, 68]), often using several of
these in combination. In some cases spatial (anatomical)
information is included in addition to intensities (e.g., [49,
67, 69]). Algorithmic approaches to segmentation optimi-
zation include methods such as Bayesian, expectation
maximization, support vector machines (e.g., [70]),
k-nearest neighbor majority voting (e.g., [64, 65], and
artificial neural networks (e.g., [71].
Although promising results are often reported for ima-
ges from a single scanner, performance on diverse datasets
can be poor due to the different tissue contrasts that may be
unknown to the algorithm. This can result in large fractions
of both false-positives and -negatives; these misclassifica-
tions have proved to be a barrier to widespread adoption,
especially in longitudinal studies if image quality varies
over time and the level of these misclassifications is
inconsistent. Incorporation of ‘‘domain knowledge’’, i.e.,
prior knowledge of the distribution of MS lesions in the
brain, improves the segmentation of lesions [67], but, in
our experience still does not deliver segmentations that are
acceptable to researchers in the field. Because of this
unreliability, practical lesion segmentation methods are
generally not fully automated, and operator intervention is
still needed at the level of individual lesions, usually by
some form feature selection based on the local maximum
intensity gradient, followed by contour following, e.g.,
[72–75]. Intra- and inter-observer reproducibilities of
contouring are better than for manual outlining [76, 77],
but the method is still labor-intensive. In order to be able to
handle the large volumes of imaging data emanating from
large therapeutic trials, it would seem appropriate to strive
for further, if not complete, automation.
Regarding automated quantification of lesion load
change, a recent review by Llado´ et al. [78] highlights the
state of the art and remaining challenges for application in a
clinical or clinical trial setting. This review includes a table
that clearly shows the lack of consistency in quantitative
performance metrics used in the literature, clearly illus-
trating the need for standardized reporting methods. Llado´
et al. classify methods for change quantification as inten-
sity-based analysis, temporal analysis, and deformation-
based analysis. An intensity-based approach to the detection
of change in lesions over time could exploit a combination
of registration and subtraction as used by Moraal et al. [32,
79, 80]. If an expert reviewer is available, the registration–
subtraction approach allows easy identification of change,
provided that the changes between timepoints due to atro-
phy are not too large, or a registration method is used that
can deal with the resulting brain shape deformations. It was
shown for 2D images that the number of changing T2
lesions observed from the beginning to the end of a trial is
statistically more powerful than the number of gadolinium-
enhancing lesions from monthly scans [80]. Duan et al. [52]
showed the feasibility of automatically quantifying these
changes in lesions from the difference images.
The methods that Llado´ et al. refer to as temporal
methods typically handle image series with a large number
of timepoints, which is an advantage over subtraction
image analysis which can only handle two timepoints at
once. The method proposed by Ait-Ali et al. [81] uses
expectation maximization to first estimate non-lesion tis-
sues and then adds lesions to the model. Gerig and col-
leagues [82] first perform segmentation of GM and WM,
and then identify active lesions based on voxel mean and
variance over the course of the timepoints. Although the
method by Gerig et al. leaves room for improvement, most
clearly regarding between-timepoint registration (assumed
to be perfect) and the model for temporal signal evolution
of MS lesions (assumed to be highly similar between
lesions), it does present a feasible approach to the multiple-
timepoint analysis of lesions.
Deformation-based methods for lesion change quantifica-
tion use the local volume change as calculated through
deformable registration methods to quantify the lesion volume
change. Two viable methods for lesion change quantification
have been presented, i.e., that by Rey et al. [83], which is based
on Thirion and Calmon [84], and that by Pieperhoff et al. [85],
but both require additional modeling or operator intervention
to indicate which are the lesion areas whose volume change
should be quantified. The lesion segmentation problem
therefore still needs to be solved in these approaches.
Three-dimensional imaging with isotropic resolution
and multiple image contrasts can be expected to further
increase the specificity with which change in lesions can be
characterized, both in terms of their spatial location and for
distinguishing and interrelating changes in different lesion
types. For all these methods, there are several choices to be
made on issues such as the type of registration, whether and
how to include prior information on expected lesion and
atrophy-related change, among others; these choices should
be informed in part by comparing results against expert
manual analysis.
Atrophy
Just as analysis of MS lesions in longitudinal studies is
affected by concomitant atrophy, so too does atrophy quan-
tification deteriorate when there are large changes in the
lesion load. For example, large changes in atrophy or in lesion
volumes may disrupt the accuracy of registration, which is
used by many atrophy measurement methods [86, 87].
In normal aging and Alzheimer’s disease (AD), Smith
et al. compared two whole-brain atrophy measurement
J Neurol (2013) 260:2458–2471 2463
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techniques, i.e., (brain) boundary shift integral (BSI [88]) and
SIENA directly and showed that the methods gave very
comparable results [89]. Sample size calculations in RRMS
showed similar sample sizes were required for BSI and SI-
ENA [90]. Using images with simulated atrophy in AD,
Camara et al. [91] confirmed the good agreement between
BSI and SIENA. More recently, Durand-Dubief et al. [6]
selected seven methods for measuring whole-brain atrophy
and assessed their reproducibility across different MRI plat-
forms. This study on nine patients scanned on three occasions
over 1 year, each time on two MRI scanners, showed that
registration-based methods, i.e., where the registration is
performed within-subject between timepoints, particularly an
optimized BSI method using k-mean clustering (KNBSI) and
Jacobian integration, gave the best agreement of whole-brain
atrophy measures between the two different MRI scanners.
Also in MS, but focusing on local change instead, Bat-
taglini et al. [92] performed a qualitative comparison
between two different methods for measuring local chan-
ges in atrophy over time. By comparing longitudinal VBM
(using FSL) and the voxelwise SIENA-R method directly,
in the same longitudinal image set from MS patients who
were scanned twice, with a 3-year interval between the two
scans, they showed that the cortical regions in which sig-
nificant atrophy was observed were roughly similar, but the
extent was very different. This result was perhaps to be
expected based on the different mechanisms of the two
methods, with VBM quantifying local GM density and its
change over time, while SIENA-R measures displacement
of the local brain-non-brain boundary. Nevertheless, this
study demonstrates the influence that choice of analysis
method has on the results. Both this difference between
SIENA-R and longitudinal VBM, and the superiority of
(within-subject) registration-based techniques may be
explained by the design of the methods: analysis methods
that analyze within-subject change over time directly, by
concurrently analyzing multiple timepoints, make use of
the fact that intra-subject variability is generally smaller
than inter-subject variability. These inherently longitudinal
methods may therefore be better at quantifying this change
than methods that treat each timepoint separately.
As indicated in the section on image acquisition, results
are also influenced by the choice of imaging parameters,
and so tissue contrast and spatial resolution should be
optimized. Nevertheless, the CLADA method proposed by
Nakamura et al. [50] did achieve both accurate measure-
ment of cortical thickness, and reliable measurement of
cortical thickness change, in low-resolution 2D images that
are (still) typical for clinical trials. Accuracy may also differ
between local atrophy measurement techniques, as shown
quantitatively by the simulated AD atrophy study by
Camara et al. [91]: deviations from ground truth atrophy
differed between two Jacobian integration methods.
Moreover, the mean absolute deviation was up to 93 % of
the ground truth volume change for hippocampus, indicat-
ing the need for further method improvement. Partly sim-
ulated image data in which the true change is known, as
used in their study, may also facilitate such developments in
MS, especially when based on representative images from
MS patients and made widely available as recommended
below.
In healthy subjects with a mean age of 56.5 years, Takao
et al. [93] investigated the effect of scanner performance on
whole-brain and local volume change measurement. They
showed that scanner drift and inter-scanner variability can
produce large apparent volumetric changes in VBM (using
SPM), including both increases and decreases. In contrast,
a recent paper on MS demonstrated that, following a
standardized imaging protocol and identical longitudinal
VBM analysis methods, the differences between centers in
the longitudinal VBM changes observed in MS patients are
much smaller than the disease-related changes, indicating
that pooling of data from different centers may be feasible
for longitudinal VBM analysis in MS [94]. These scanner
effects are important issues in most large-scale studies in
MS, and this discrepancy merits further investigation.
Available methods and proposed direction
Table 2 lists the currently available methods for lesion load
and atrophy measurement. The list is restricted to those
methods that are available for installing locally on the
researchers’ own systems (not necessarily without charge).
The merits and limitations of each method are briefly
indicated. It is clear from the discussion of published
methods above that far more methods have been developed
than just the selection listed in Table 2 that are available for
installing locally. This suggests that further improvement of
MS research may be achieved by wider distribution of some
of these methods. An objective evaluation of the perfor-
mance of those methods should then be a first step. In order
to distinguish between disease-related effects (different
disease types, patient selection, follow-up durations, etc.)
and method-related effects, such comparisons between
analysis methods should be performed using the same
common dataset(s). A database such as that proposed under
recommendation (3) would facilitate such a comparison.
Standard test dataset
Position statement
A standard dataset with benchmark results should be set up
to facilitate development, calibration, and objective eval-
uation of image analysis methods for MS.
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Reasoning
Comparing the performance of one method for lesion load
or atrophy measurement to another is difficult due to the
lack of standardized representative data. Papers describing
new methods do not always compare the new method to
current ones, and even if they do, the test image dataset is
rarely made available to the larger research community.
Finally, different papers use different metrics to report
performance of their algorithms. Hence, the results cannot
be reproduced in detail, nor can they realistically be
compared between methods.
In order to allow investigators to select an analysis
method, based on an unbiased assessment of various
alternatives, one possible approach is to create annotated
longitudinal MR image datasets from carefully selected
and representative MS patients from multiple scanners/
centers. This database would consist of different subsets of
images for addressing specific questions. The database
should be accompanied by the framework necessary for
carrying out objective and quantitative evaluation of dif-
ferent methods against ‘‘gold standard’’ expert annotations,
including standards for reporting the results of those
comparisons, and thereby facilitate an unbiased and
transparent assessment of image analysis methods.
Several databases are available that meet some of these
requirements. First, BrainWeb (http://www.bic.mni.mcgill.
ca/brainweb/) [95] offers a simulated dataset in which, for
a limited number of cases with MS lesions, image char-
acteristics such as intensity spatial inhomogeneity and
noise can be varied. Such data could be expanded by
including a larger range of lesion volumes and degrees of
atrophy in the simulated images. Inserting artificial lesions
into images obtained from healthy controls is an approach
followed in several papers assessing lesion segmentation or
the effect of lesions on atrophy measurement. The advan-
tages of this approach are that the effects of lesions can be
studied in isolation, and that the ground truth is known. The
main disadvantage is that healthy control images may not
be similar to MS patients’ images in all respects; for
example, the degree of brain atrophy may differ, or ‘‘dirty’’
WM may be present in MS patients while it is generally
absent in healthy controls. Therefore, a test dataset should
not be restricted to simulated images based on healthy
control data, but should also include real patient data.
The image data for the MICCAI 2008 ‘‘MS lesion
segmentation challenge’’ do consist of real patient data,
derived from a relatively large set of patients; these data
are still available online (http://www.ia.unc.edu/MSseg/).
The website provides a test-set of images along with expert
annotations, so that results of a segmentation method can
be compared to the ‘‘gold standard’’ segmentation. The
scores obtained using the different methods that have beenT
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tested are listed on the website, and new entries are still
being frequently added. This is a good example of the kind
of standardized test dataset that is needed for optimizing
analysis methods in MS. However, some characteristics of
the imaging data, such as the spatial resolution of the
images, are different from those typically used in a clinical
trial setting. Furthermore, in addition to the 2D-FLAIR
images that form the dataset, different pulse sequence types
such as 3D-FLAIR or 2D dual-echo PD/T2 are also needed
to test the robustness of lesion segmentation methods, as
well as images such as DIR for GM lesion segmentation.
For developing and optimizing atrophy measurement
methods, 3D T1-weighted anatomical images using a pulse
sequence such as MP-RAGE are required. The ADNI
database for AD, mild cognitive impairment and healthy
aging may serve as a good example here (http://
adni.loni.ucla.edu/) [96]; it allows researchers to down-
load and use image data, under certain conditions. ADNI
has boosted the development of brain image analysis
methods [97], thereby also improving MS research. The
availability of two consecutively acquired MP-RAGE
scans provides an opportunity to study the reproducibility
of methods [98], and including similar scan-rescan data in
an MS test dataset would be highly desirable. Another
example is the OASIS project, which allows researchers to
freely download a dataset that contains images of adults
across a large age range, including demented and non-
demented elderly (http://www.oasis-brains.org/, [99]). The
OASIS dataset also contains short-term rescan images for
reliability analyses.
Objectively quantifying the performance of lesion seg-
mentation techniques is particularly challenging, since
experts do not generally agree completely on which voxels
should be considered as part of a lesion [100, 101]. Seg-
mentation of cortical and subcortical GM presents similar
problems. Derakshan et al. [9] performed an elegant
comparison between six automated methods and six expert
segmentations. Their study showed not only how well the
automated methods performed compared to the average
expert segmentations, but importantly it also highlighted
the variability between experts, which should be taken into
account in setting up a database. One of the first uses of the
proposed database could be to investigate inter-expert
variability, and possibly standardize manual outlining
methods in order to improve the validation of automated
methods for quantifying lesion volume change and atrophy
rates in MS.
Finally, beyond providing test datasets, the utility could
serve the analysis method development community even
better by providing training data sets. The MICCAI MS
lesion challenge has been mentioned above, and the sus-
tained availability of those data allows further development
of MS lesion segmentation methods. However, there is a
real danger that without independent training data, further
apparent improvements may not generalize when the
methods are applied in new image datasets with different
imaging characteristics. Therefore, it seems imperative that
to make real progress, training data should be made
available that captures the variability that is encountered in
a real clinical or trial setting, not only the variability due to
inter-patient differences, but also that due to the hetero-
geneity of scanners and imaging protocols.
Conclusions
Data collection and analysis methods for longitudinal MR
imaging studies of brain lesion load and brain atrophy in
MS have proved to be of great value, but can be improved.
We propose to (1) acquire images using 3D acquisition
techniques with multiple contrasts and near isotropic spa-
tial resolution; (2) integrate the segmentation of lesions and
atrophy measurement; and (3) provide a standard test
dataset containing both images and expert annotations for
objective testing and evaluation of analysis methods. These
points should prove complementary: the standard test
dataset may facilitate development and improvement of the
integrated segmentation techniques, which in turn would
benefit from the isotropic spatial resolution of the
acquisition.
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